Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and
tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for
pre-exposure prophylaxis (PrEP) in women exposed to high HIV risk through vaginal
acquisition. Adherence to the one pill per day regimen is crucial for its effectiveness in
reducing the risk of acquiring HIV. Currently, there is no available point of care diagnostic
test to quickly measure blood levels of tenofovir in the clinic. This study will determine
whether a tenofovir (TFV) aptamer-based biosensor (aptasensor) can detect TFV in biological
fluids from women randomized to different dosing regimens representing high and low
adherence.